Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

corporate branding

- PMLiVE

Novartis, Boehringer stake claims to combination COPD market

Includes combination follow-up to Spiriva

- PMLiVE

Boehringer unveils large study in stroke prevention

Will assess benefits of Pradaxa

german flag

Boehringer criticises German drug price freeze

And repeats demand for update of HTA system

National Institute for Health and Care Excellence NICE logo

NICE backs two cancer drugs

Boehringer’s Giotrif and Janssen’s Velcade given final go-ahead for NHS use

- PMLiVE

Boehringer lines up biosimilars of major drugs

Prospects include copies of Humira, Avastin and MabThera

- PMLiVE

Boehringer plans to open trial data back to 1998

Will partner with Sanofi, GSK, Roche, Novartis and ViiV Healthcare on online platform

- PMLiVE

Boehringer’s Pradaxa wins FDA backing for DVT

 Anticoagulant sees uses expanded in the US

National Institute for Health and Care Excellence NICE logo

Boehringer cancer drug on course for NHS use in UK

NICE backs Giotrif in draft guidance

- PMLiVE

Boehringer switches diabetes candidate in Zealand collaboration

Will swap ZP2929 for another GLP-1 receptor agonist

- PMLiVE

Boehringer names new UK MD

Zinta Krumins has been with company for 25 years

- PMLiVE

FDA to assess safety of Boehringer’s Pradaxa

US regulator plans study to compare the anticoagulant with warfarin

- PMLiVE

Survey to gauge impact of doctor-patient talks in diabetes

Lilly and Boehringer sponsor worldwide study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links